DEVELOPMENT OF A TECHNOLOGY FOR PRODUCING A STABLE INJECTABLE DOSAGE FORM OF A HYDROPHOBIC INDOLOCARBAZOLE DERIVATIVE

Authors

  • MARIA DMITRIEVA N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
  • ALEXANDER KOLPAKSIDI N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
  • OLGA ORLOVA N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
  • ELENA IGNATYEVA N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
  • ANNA LANTSOVA N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
  • LUDMILA NIKOLAEVA Sechenov University, Moscow, Russia
  • IVAN KRASNYUK Sechenov University, Moscow, Russia

DOI:

https://doi.org/10.22159/ijap.2021v13i6.42685

Keywords:

hydrophobic indolocarbazole derivative, dimethyl sulfoxide, solubilization, dosage form, freeze drying, concentrate

Abstract

Objective: Development of a technology for production of a stable injectable dosage form (IDF) of indolocarbazole derivative LHS-1269.

Methods: LHS-1269 is an active pharmaceutical ingredient that was synthesized in the N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. The IDF includes dimethyl sulfoxide (DMSO), 95% ethanol, Kollidon® 17PF and water for injection. Magnetic stirrer and overhead stirrer with a propeller stirring element were used to prepare the model solution of the IDF of LHS-1269. Sterilizing filtration of the solution was performed with 0.2−0.22 um polycarbonate, cellulose, polyvinylidene fluoride, polyethersulfone and nylon membrane filters. The aqueous solution of LHS-1269 were lyophilized in Edwards Minifast DO.2 freeze dryer. Assay of LHS-1269 was performed by spectrophotometry at 320±3 nm. Potentiometry was used to measure pH, a viscosimetry method was used to measure viscosity of the solutions. The average weight was estimated by weighing a sample of 10 vials with the concentrate.

Results: 0.5% aqueous solution of LHS-1269 was produced by mixing the solution of the active substance in DMSO and ethanol with an aqueous solution of polyvinylpyrrolidone gradually at the ratio of LHS-1269/DMSO/ethanol/Kollidon® of 1/11/32/40 by weight. The aqueous solution of the study substance cannot be lyophilized, so a sequence of technological operations was presented to produce an anhydrous concentrate “LHS-1269, concentrate for solution for injection and infusion 25 mg”.

Conclusion: A technology was developed to produce a stable IDF of a hydrophobic indolocarbazole derivative LHS-1269, a high-potential antitumor drug.

Downloads

Download data is not yet available.

References

Zenkov RG, Ektova LV, Vlasova OA, Belitsky GA, Yakubovskaya MG, Kirsanov KI. Indolo [2,3-a]carbazoles: diversity, biological properties, application in antitumor therapy. Chem of heterocyc comp 2020;56:644−58.

Kiseleva MP, Pokrovsky VS, Tatarskiy VV, Borisova LM, Golubeva IS, Ektova LV. Indolocarbazole derivatives − a promising class of anticancer drugs. Russ J of Biother 2018;4:20−26.

Apryshko GN, Zhukova OS, Fetisova LV, Vlasenkova NK, Pugacheva RB, Goryunova OV. In silico and in vitro research of potential antineoplastic amino acid derivatives of indolocarbazole glycosides properties. Russ J of Biother 2017;4:46−54.

Melnik SYa, Vlasenkova NK, Garaeva LD, Golubeva IS, Goryunova OV, Eremina VA et al. Method for the preparation of N-glycosides of indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-diones with cytotoxic and antitumor activity. Patent No. 2427585 C1 Russian Federation: publ. of 10.12.2009

Golubeva IS, Yavorskaya NP, Ektova LV, Dmitrieva MV, Borisova LM, Eremina VA et al. Antitumor activity of some derivatives of indolo[2,3-a]carbazoles N-glycosides with xylose carbohydrate residue. Russ J of Biother 2020;19:86–93 (In Russ.)

Golubeva IS, Eremina VA, Moiseeva NI, Ektova LV, Yavorskaya NP. A derivative of the N-glycoside class indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-diones - N-{ 12-(β-D-xylopyranosyl)-5,7-dioxo-indolo[2,3-a]pyrrolo[3,4-c] carbazol-6-yl} pyridine-2-carboxamide, with cytotoxic and antitumor activity. Patent No. 2667906 C1 Russian Federation: publ. 25.09.2018.

Vartanian A, Baryshnikova M, Burova O, Afanasyeva D, Misyurin V, Belyаvsky A et al. Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents. Melanoma Res. 2017;1:8−16.

Vartanyan AA, Baryshnikova MV, Eremina VA, Miniker TD, Tikhonova NI, Kuzmina NE et al. Indolocarbazole derivatives blocking vasculogenic mimicry in tumors. Patent No. 2557554 C1 Russian Federation: publ. 27.07.2015

Kolluru LP, Atre P, Rizvi SAA. Characterization and Applications of Colloidal Systems as Versatile Drug Delivery Carriers for Parenteral Formulations. Pharmaceut (Basel) 2021;2:108.

Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.

Sopyan I, Syah ISK, Nurhayti D, Budiman A. Improvement of simvastatin dissolution rate using derivative non-covalent approach by solvent drop grinding method. Inter J Appl Pharm. 2020;1:21−4.

Gulyakin I, Lantsova A, Nikolaeva L, Dmitrieva M, Oborotova N, Orlova O, Zhuravleva N. Features of the development of a lyophilized injectable dosage form of the original anticancer drug LCS-1208. Inter J Appl Pharm 2021;13:102−5. https://doi.org/10.22159/ijap.2021v13i4.41371.

Seager H, Taskis CB, Syrop M, Lee TJ. Structure of products prepared by freeze-drying solutions containing organic solvents. J Parent Sci Technol 1985:161–79.

Published

21-09-2021

How to Cite

DMITRIEVA, M., KOLPAKSIDI, A., ORLOVA, O., IGNATYEVA, E., LANTSOVA, A., NIKOLAEVA, L., & KRASNYUK, I. (2021). DEVELOPMENT OF A TECHNOLOGY FOR PRODUCING A STABLE INJECTABLE DOSAGE FORM OF A HYDROPHOBIC INDOLOCARBAZOLE DERIVATIVE. International Journal of Applied Pharmaceutics, 13(6). https://doi.org/10.22159/ijap.2021v13i6.42685

Issue

Section

Original Article(s)